FOLH1 and prostate carcinoma: In more recent years, PSMA, a transmembrane glycoprotein highly expressed on the cell surface of prostate cancer cells, with expression increasing with more aggressive cancer types and in castration-resistant disease, has emerged as a compound of utmost importance for imaging and therapy of prostate cancer [74].